CoChat
Sign Up
Cited by 623Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The Alzheimer’s Disease Clinical Spectrum

Open access
Atri, Alireza·2019·Medical Clinics of North America
DOI 10.1016/j.mcna.2018.10.009
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making. When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. AD biopathologic processes develop over decades before symptoms manifest; this period is increasingly targeted in research as an opportunity to best delay or prevent AD dementia.

AI snapshot

Written from the paper’s full text.

TL;DR

This review summarizes the clinical spectrum, diagnostic evaluation, and multifactorial management of Alzheimer’s disease (AD) and AD-related dementias. It emphasizes structured history, multidomain assessment, tiered testing, and modest but meaningful benefits from FDA-approved cholinesterase inhibitors and memantine alongside nonpharmacologic care.

Key findings

  • AD is the most common cause of cognitive impairment/dementia in people older than 65 years; dementia prevalence approximately doubles every 5 years from age 65 to 85, rising from about 1%–2% at 65 years to more than 30%–50% by 85 years. Among Americans older than 60 years, 16% have MCI, equating to 11.6 million individuals.
  • Amnestic MCI is greater than 90% associated with underlying AD pathology; MCI increases annual progression to dementia (relative risk 6–8), and MCI with positive AD pathology biomarkers versus negative biomarkers has a 2–3 relative risk of progression (8% vs 17%–22% per year).
  • Diagnosis remains clinical, using a 3-step formulation: identify level of impairment, define the cognitive-behavioral syndrome, and establish likely cause(s) with multitiered laboratory and neuroimaging tests. CSF and amyloid PET biomarkers are clinically available but not indicated in most symptomatic individuals; they are reserved for atypical, rapidly progressive, early-onset, or inconclusive cases.
  • Management is multifactorial: nonpharmacologic/behavioral approaches are first-line for neuropsychiatric symptoms; FDA-approved anti-AD drugs (donepezil, galantamine, rivastigmine, memantine) provide modest benefits. During initial 6–12 months, cognition/ADL/behavior/global change may improve in 10%–30%, plateau in 30%–50%, or continue to deteriorate in 20%–40%; discontinuation of cholinesterase inhibitors is on aggregate harmful.

Methods

  • Review article synthesizing clinical criteria, guidelines, and evidence for AD diagnosis and management; no primary study sample or new data collection is reported.
  • Draws on major criteria (2011 NIA-AA, International Working Group, DSM-5, 2018 NIA-AA research framework), randomized controlled trials, meta-analyses, open-label extensions, and prospective observational cohort studies.
  • Main analysis is narrative synthesis with clinical recommendations, including tables for risk factors, history/symptom-function review, tiered testing, differential diagnosis, and FDA-approved medication dosing.

Limitations

  • The paper does not include a stated limitations section.
  • Evident from the text: it is a narrative clinical review without a described systematic search strategy or formal evidence-quality appraisal; recommendations rely on cited guidelines, trials, meta-analyses, and observational cohort studies.
  • Evident from the text: the author discloses honoraria for consulting, educational lectures/programs/materials, or advisory boards from multiple pharmaceutical companies and institutional investigational study/trial funding.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.mcna.2018.10.009

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 159 cited sources checked · 0 supported · 0 flagged

  • Interpretationnone given

    MCI and dementia due to AD can be accurately diagnosed by a comprehensive evaluation that integrates pathologic AD biomarkers (cerebrospinal fluid [CSF] and amyloid PET).

    “MCI and dementia due to AD can be accurately diagnosed by a comprehensive evaluation that integrates pathologic AD biomarkers (cerebrospinal fluid [CSF] and amyloid PET).”
    Quote in the paperNot a substantial claim
  • Premisecitation

    Clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.

    “However, clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [10] Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association, Alzheimers Dement source

      Not checked in the free run.

    • cites [11] Simonsen, 2017, Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia, Alzheimers Dement source

      Not checked in the free run.

  • Premisecitation

    AD-related pathological changes often coexist with 1 or more other pathologies, particularly vascular-ischemic cerebral injury and diffuse Lewy body (DLB) disease.

    “AD-related pathological changes often coexist with 1 or more other pathologies, particularly vascular-ischemic cerebral injury and diffuse Lewy body (DLB) disease.1,[6][7][8][9]”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [1] Livingston, 2017, Dementia prevention, intervention, and care, Lancet source

      Not checked in the free run.

    • cites [6][7][8][9]

      Not checked in the free run.

  • Premisecitation

    AD CSF and PET biomarkers are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.

    “These tests are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.10,11”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [10] Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association, Alzheimers Dement source

      Not checked in the free run.

    • cites [11] Simonsen, 2017, Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia, Alzheimers Dement source

      Not checked in the free run.

  • Premisecitation

    The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for AD recognizes nonamnestic AD presentations that include language, visuospatial, and executive dysfunction features.

    “The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for AD recognizes nonamnestic AD presentations that include language, visuospatial, and executive dysfunction features.32”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [32] McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement source

      Not checked in the free run.

  • Classified as probably not a substantial claim. 18
  • May combine two claims. 29

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    AD is the sixth leading cause of death in the United States and the only top-10 cause still significantly increasing.

    “AD is the sixth leading cause of death in the United States and the only top-10 cause still significantly increasing.4”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [4] Alzheimer’s Association, 2018, 2018 Alzheimer's disease facts and figures, Alzheimers Dement source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Alzheimer's disease (AD) is the most common cause of cognitive impairment or dementia in individuals older than 65 years.

    “Alzheimer's disease (AD) is the most common cause of cognitive impairment or dementia in individuals older than 65 years”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [1][2][3][4][5]

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    With rising longevity, a worldwide pandemic of mild cognitive impairment (MCI), AD, and AD-related dementia (ADRD) is anticipated.

    “with rising longevity, a worldwide pandemic of mild cognitive impairment (MCI), AD, and AD-related dementia (ADRD) is anticipated.[1][2][3][4][5]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [1][2][3][4][5]

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Symptoms too often go undiagnosed, misattributed, or dismissed and ignored, which causes distressing, costly, and potentially harmful delays in receiving appropriate care.

    “Symptoms too often go undiagnosed, misattributed, or dismissed and ignored, which causes distressing, costly, and potentially harmful delays in receiving appropriate care.1,4,5”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [1] Livingston, 2017, Dementia prevention, intervention, and care, Lancet source

      Not checked in the free run.

    • cites [4] Alzheimer’s Association, 2018, 2018 Alzheimer's disease facts and figures, Alzheimers Dement source

      Not checked in the free run.

    • cites [5] Prince, 2015

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.

    “The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [2] Deschaintre, 2009, Treatment of vascular risk factors is associated with slower decline in Alzheimer's disease, Neurology source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages.

    “It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages. 2”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [2] Deschaintre, 2009, Treatment of vascular risk factors is associated with slower decline in Alzheimer's disease, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In the dementia stages of AD, many patients have cortical or cortico-subcortical microhemorrhages due to cerebral amyloid angiopathy-related vasculopathy and leakage; hemosiderin microdeposition from microhemorrhages are seen on gradient-echo or susceptibility-weighted MRI sequences in 15% to 20% of patients.

    “In the dementia stages of AD, many patients have cortical or cortico-subcortical microhemorrhages due to cerebral amyloid angiopathy-related vasculopathy and leakage 19 ; hemosiderin microdeposition from microhemorrhages are seen on gradient-echo or susceptibility-weighted MRI sequences in 15% to 20% of patients.20”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [19] Attems, 2011, Review: sporadic cerebral amyloid angiopathy, Neuropathol Appl Neurobiol source

      Not checked in the free run.

    • cites [20] Atri, 2005, Prevalence and effects of lobar microhemorrhages in early-stage dementia, Neurodegener Dis source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Prevailing models posit a central role of accumulation of synaptic neurotoxic forms of Aβ to induce inflammatory and microglial cascades, broad ionic and neurotransmitter abnormalities, mitochondrial dysfunction, oxidative stress, and hyperphosphorylation of the microtubule stabilizing protein tau and formation of tangles.

    “Prevailing models posit a central role of accumulation of synaptic neurotoxic forms of Aß to induce inflammatory and microglial cascades, broad ionic and neurotransmitter abnormalities, mitochondrial dysfunction, oxidative stress, and hyperphosphorylation of the microtubule stabilizing protein tau and formation of tangles.[26][27][28][29][30][31]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [26][27][28][29][30][31]

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    APOE-ε4 alleles are associated with accelerated Aβ-deposition and earlier onset and higher risk of developing AD symptoms.

    “APOE-ε4 alleles are associated with accelerated Aß-deposition and earlier onset and higher risk of developing AD symptoms.21,23”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [21] Loy, 2014, Genetics of dementia, Lancet source

      Not checked in the free run.

    • cites [23] Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Patterns of change may overlap but are not part of normal cognitive aging, as manifested by differential aging and AD effects on cognitive networks.

    “Patterns of change may overlap but are not part of normal cognitive aging, as manifested by differential aging and AD effects on cognitive networks.34”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [34] Chhatwal, 2018, Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing, Brain source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The 3 major clinical criteria for the AD spectrum are the revised 2011 NIA-AA criteria, the International Working Group 2010 revised new lexicon criteria, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.

    “The 3 major clinical criteria for the AD spectrum are the revised 2011 NIA-AA criteria, 32,39 the International Working Group (Dubois and colleagues 39,40 ) 2010 revised new lexicon criteria, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.41”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [32] McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement source

      Not checked in the free run.

    • cites [39] Dubois, 2010, Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol source

      Not checked in the free run.

    • cites [40] Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Performance on measures of fluid intelligence, such as speed of mental processing; working memory; recall and retention of verbal and visual information; and reasoning begin to decline in many individuals from age 20 to 30 years.

    “Performance on measures of fluid intelligence, such as speed of mental processing; working memory; recall and retention of verbal and visual information (learning and memory), in particular visuospatial memory; and reasoning begin to decline in many individuals from age 20 to 30 years.134,135”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [134] Salthouse, 2009, When does age-related cognitive decline begin?, Neurobiol Aging source

      Not checked in the free run.

    • cites [135] Weintraub, 2013, Cognition assessment using the NIH Toolbox, Neurology

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    In the most common form of AD, sporadic late-onset AD, many genetic variations contribute to increase or lower risk; greater than 20 have been identified.

    “In the most common form of AD, sporadic late-onset AD, many genetic variations contribute to increase or lower risk; greater than 20 have been identified (AlzGene Database; www.alzgene.org).22”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [22] Bertram, 2007, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database, Nat Genet source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    Dementia-level impairment requires cognitive or behavioral symptoms of sufficient magnitude to interfere with usual work or daily function.

    “dementia-level impairment requires cognitive or behavioral symptoms”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [32] McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    AD is a dual proteinopathy disease defined by a widespread but regionally specific pattern of intraparenchymal diffuse and neuritic β-amyloid (Aβ) plaques and intracytoplasmic then extracellular neurofibrillary tangles with synaptic and neuronal loss and gliosis.

    “AD is a dual proteinopathy disease defined by a widespread but regionally specific pattern of intraparenchymal diffuse and neuritic ß-amyloid (Aß) plaques and intracytoplasmic (initially), then extracellular, neurofibrillary tangles with synaptic and neuronal loss and gliosis.[14][15][16][17]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [14][15][16][17]

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Familial autosomal dominant AD is rare (<1%), usually manifests in early-onset AD (onset age <65 years; <4% of AD), and is caused by mutations in presenilin 1, amyloid precursor protein, or presenilin 2.

    “Familial autosomal dominant AD is rare (<1%), usually manifests in early-onset AD (onset age <65 years; <4% of AD), and is caused by mutations in presenilin 1, amyloid precursor protein, or presenilin 2. 21”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [21] Loy, 2014, Genetics of dementia, Lancet source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    MCI diagnosis is a matter of clinical judgment made by a skilled clinician regarding the presence of cognitive impairment without significant interference in the ability to function at work or in usual daily activities, and must be individualized to the patient.

    “MCI diagnosis is a matter of”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [32] McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement source

      Not checked in the free run.

    • Rests on an assumption: AD clinical syndromes, Cognitive-Behavioral Syndromes (CBS) presumed to be due to AD, are heterogeneous, particularly in younger individuals (65 years of age or younger).

  • May combine two claims.

    Premisecitation

    Neuropsychiatric symptoms or problem behaviors in AD dementia are associated with more rapid decline, earlier institutionalization, higher distress, worse quality of life, and greater health care utilization and costs.

    “which are associated with more rapid decline, earlier institutionalization, higher distress, worse quality of life, and greater health care utilization and costs.53,54”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [53] Okura, 2012, Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study, J Am Geriatr Soc source

      Not checked in the free run.

    • cites [54] Kales, 2005, Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression, Am J Geriatr Psychiatry source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The AD-8 screening instrument provides a practical symptoms questionnaire for changes in thinking and memory that can be a red flag for ADc syndromes.

    “The AD-8 screening instrument provides a practical symptoms questionnaire for changes in thinking and memory that can be a red flag for ADc syndromes.43”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [43] Galvin, 2005, The AD8: a brief informant interview to detect dementia, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Presence of pathologic AD does not exclude other pathologies causing or contributing to the patient's CBS; for example, 70% to 80% of individuals with DLB are also amyloid-positive on PET.

    “Presence of pathologic AD does not exclude other pathologies causing or contributing to the patient's CBS; for example, 70% to 80% of individuals with DLB are also amyloid-positive on PET.46”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [46] Gomperts, 2008, Imaging amyloid deposition in Lewy body diseases, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Short-term and long-term antipsychotic use is associated with substantial risk of cognitive decline, morbidity (parkinsonism, falls, pneumonia, cardiovascular and cerebrovascular events), and mortality.

    “Short-term and long-term antipsychotic use is associated with substantial risk of cognitive decline, morbidity (eg, parkinsonism, falls, pneumonia, or cardiovascular and cerebrovascular events), and mortality.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [55] Ballard, 2014, Prescription of antipsychotics in people with dementia, Br J Psychiatry source

      Not checked in the free run.

    • cites [56] Kales, 2015, Assessment and management of behavioral and psychological symptoms of dementia, BMJ source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A recent systematic review and meta-analysis by Tricco and colleagues included 110 studies and 23,432 subjects and supports efficacy, effectiveness, and safety of anti-AD therapies.

    “A recent systematic review and meta-analysis by Tricco and colleagues 64 included 110 studies and 23,432 subjects supports efficacy, effectiveness, and safety.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [64] Tricco, 2018, Comparative effectiveness and safety of cognitive enhancers for treating alzheimer's disease: systematic review and network metaanalysis, J Am Geriatr Soc source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Co-existent Alzheimer disease and vascular-ischemic pathology, and Alzheimer disease with dementia with Lewy bodies pathology, are prevalent in older individuals.

    “Co-existent AD and vascular-ischemic pathology (causing the clinical spectrum of VCI, which includes dementia), and AD with DLB pathology (causing AD-DLB The Alzheimer's Clinical Spectrum variants), are prevalent in older individuals.9,49,50”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [9] Kapasi, 2017, Impact of multiple pathologies on the threshold for clinically overt dementia, Acta Neuropathol source

      Not checked in the free run.

    • cites [49] Jellinger, 2008, Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease, Acta Neuropathol source

      Not checked in the free run.

    • cites [50] Schneider, 2007, Mixed brain pathologies account for most dementia cases in community-dwelling older persons, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Cholinesterase inhibitors and memantine demonstrate acceptable tolerability and safety profiles.

    “ChEIs and memantine also have complementary mechanisms of action, potentially additive effects, and demonstrate acceptable tolerability and safety profiles.63”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [63] Atri, 2013, Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy, Alzheimers Res Ther source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    Cholinesterase inhibitors and memantine are recommended broadly in consensus guidelines and practice parameters for AD dementia.

    “Cholinesterase inhibitors (ChEIs) (donepezil, galantamine, rivastigmine) and the N-methyl-D-aspartate (NMDA)-antagonist, memantine, are the only FDA-approved treatments for AD dementia and are recommended broadly in consensus guidelines and practice parameters.1,52,61,62”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [1] Livingston, 2017, Dementia prevention, intervention, and care, Lancet source

      Not checked in the free run.

    • cites [52] National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NG97). NICE, UK, June 20, 2018.

      Not checked in the free run.

    • cites [61] Schmidt, 2015, EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease, Eur J Neurol source

      Not checked in the free run.

    • cites [62] Gauthier, 2012, Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4), Can Geriatr J source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Anti-AD therapies delay nursing home placement without prolongation of time to death.

    “and to delay nursing home placement without prolongation of time to death.64,65”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [64] Tricco, 2018, Comparative effectiveness and safety of cognitive enhancers for treating alzheimer's disease: systematic review and network metaanalysis, J Am Geriatr Soc source

      Not checked in the free run.

    • cites [65] Rountree, 2013, Effectiveness of antidementia drugs in delaying Alzheimer disease progression, Alzheimers Dement source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Sustained anti-AD treatments provide a modest expectation of short-term stabilization or improvement, and longer-term slowing of clinical decline.

    “Sustained treatments provide a modest expectation of short-term stabilization or improvement, and longer-term slowing of clinical decline.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    In the long run, current treatments of AD dementia mitigate decline but do not prevent it.

    “In the long run, current treatments of AD dementia mitigate decline but do not prevent it.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In more than 40 short-term randomized controlled trials using placebos over 24 to 52 weeks and in meta-analyses of randomized controlled trials, all 3 cholinesterase inhibitors have demonstrated small to medium effect size treatment benefits at the subject-group level in improving, stabilizing, or delaying decline in cognition, activities of daily living, and global status, and in ameliorating BPS

    “In more than 40 short-term randomized controlled trials (RCTs) using placebos over 24 to 52 weeks investigating efficacy, and in meta-analyses of RCTs, all 3 ChEIs have demonstrated small to medium effect size treatment benefits at the sibject-group level in terms of improving, stabilizing, or delaying decline in cognition, ADL, and global status, and in ameliorating BPSD and caregiver burden.35,”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [35] Farlow, 2007, Effective pharmacologic management of Alzheimer's disease, Am J Med source

      Not checked in the free run.

    • cites [65] Rountree, 2013, Effectiveness of antidementia drugs in delaying Alzheimer disease progression, Alzheimers Dement source

      Not checked in the free run.

    • cites [70] Farlow, 2000, A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, Eur Neurol source

      Not checked in the free run.

    • cites [71] Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, N Engl J Med source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Level II or equivocal level I evidence suggest donepezil treatment may be beneficial in very mild stage AD or for subgroups with MCI due to AD (carriers of APOE-ε4 allele, those with depression or depressive symptoms).

    “Level II or equivocal level I evidence suggest donepezil treatment may be beneficial in very mild stage AD or for subgroups with MCI due to AD (ie, carriers of APOE-ε4 allele, 96 those with depression or depressive symptoms 97 ).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [96] Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med source

      Not checked in the free run.

    • cites [97] Lu, 2009, Donepezil delays progression to AD in MCI subjects with depressive symptoms, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Even temporary discontinuation of cholinesterase inhibitors is associated with irreversible declines and greater risk of nursing home placement.

    “Even temporary discontinuation is associated with irreversible declines and greater risk of nursing home placement.[67][68][69][70][71][72]”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [67] Raskind, 2000, Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 study group, Neurology source

      Not checked in the free run.

    • cites [68] Courtney, 2004, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, Lancet source

      Not checked in the free run.

    • cites [69] Doody, 2001, Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease, Arch Neurol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Memantine treatment benefits include improvement, stabilization, or reduced decline in cognition, function (activities of daily living), and global status, and amelioration of behavioral and psychological symptoms of dementia and caregiver burden.

    “Treatment benefits include improvement, stabilization, or reduced decline in the domains of cognition, function (ADLs), and global status; and by amelioration of BPSD and caregiver burden.63,71,73,[98][99][100][101][102][103][104][105][106][107][108][109][110][111]”
    Quote in the paperSubstantial claim0 of 10 sources checked
    • cites [63] Atri, 2013, Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy, Alzheimers Res Ther source

      Not checked in the free run.

    • cites [71] Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, N Engl J Med source

      Not checked in the free run.

    • cites [73] Weycker, 2007, Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil, Curr Med Res Opin source

      Not checked in the free run.

    • cites [98] McShane, 2006, Memantine for dementia, Cochrane database Syst Rev

      Not checked in the free run.

    • cites [99] Winblad, 1999, Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine), Int J Geriatr Psychiatry source

      Not checked in the free run.

    • cites [100] Reisberg, 2003, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med source

      Not checked in the free run.

    • cites [101] Bullock, 2006, Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date, Alzheimer Dis Assoc Disord source

      Not checked in the free run.

    • cites [102] Doody, 2004, Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease, Demenr Geriatr Cogn Disord source

      Not checked in the free run.

    • cites [103] Grossberg, 2009, Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease, Dement Geriatr Cogn Disord source

      Not checked in the free run.

    • cites [104] Schmitt, 2006, Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis, Alzheimer Dis Assoc Disord source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Short-term (6 months or less) memantine treatment effect sizes are small to medium and clinically significant at the moderate to severe stages of AD.

    “Short-term (6 months or less) memantine treatment effect sizes are small to medium in size and clinically significant at the moderate to severe stages of AD. 109,110,112,113”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [109] Winblad, 2007, Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials, Dement Geriatr Cogn Disord source

      Not checked in the free run.

    • cites [110] Livingston, 2004, The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis, Int J Geriatr Psychiatry source

      Not checked in the free run.

    • cites [112] Abbott, 2009, All-sky LIGO search for periodic gravitational waves in the early fifth-science-run data, Phys Rev Lett source

      Not checked in the free run.

    • cites [113] Wilkinson, 2009, Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease, Dement Geriatr Cogn Disord source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    The benefits of anti-AD medications may also extend to reducing antipsychotic use.

    “The benefits may also extend to reducing antipsychotic use.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Persistence, higher dosage (in later dementia stages), and duration of treatment are associated with better outcomes, even in those with advanced dementia.

    “Persistence, higher dosage (in later dementia stages), and duration of treatment are associated with better outcomes, even in those with advanced dementia.92,95,114,115,130”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [92] Wattmo, 2011, Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment, Alzheimer Dis Assoc Disord source

      Not checked in the free run.

    • cites [95] Wallin, 2011, Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting, Neuropsychiatr Dis Treat source

      Not checked in the free run.

    • cites [114] Atri, 2008, Long-term course and effectiveness of combination therapy in Alzheimer disease, Alzheimer Dis Assoc Disord source

      Not checked in the free run.

    • cites [115] Rountree, 2009, Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease, Alzheimers Res Ther source

      Not checked in the free run.

    • cites [130] Wattmo, 2011, Predictors of long-term cognitive outcome in Alzheimer's disease, Alzheimers Res Ther source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    The FDA-approved anti-AD pharmacotherapies (cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and memantine) can reduce progression of clinical symptoms and disability.

    “The FDA-approved anti-AD pharmacotherapies; the ChEIs donepezil, galantamine, and rivastigmine; and the NMDA antagonist memantine can reduce progression of clinical symptoms and disability.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Large randomized controlled trials have failed to support benefits from ginkgo biloba, high-dose vitamin B12 or folic acid combinations, omega-3 fatty acid or fish oil components or preparations, nonsteroidal anti-inflammatory drugs, and statin medications at the dementia stage of AD.

    “Unfortunately, large RCTs have failed to support benefits from ginkgo biloba, high-dose vitamin B 12 or folic acid combinations, omega-3 fatty acid or fish oil components or preparations, nonsteroidal anti-inflammatory drugs, and statin medications at the dementia stage of AD. 76,81”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [76] Tayeb, 2012, Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors, Pharmacol Ther source

      Not checked in the free run.

    • cites [81] Ballard, 2011, Alzheimer's disease, Lancet source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The rates of discontinuation due to adverse events for cholinesterase inhibitor and memantine combination treatment are low, between 5% to 10%, and not generally significantly different from placebo.

    “The rates of discontinuation due to adverse events for ChEIs and memantine combination treatment are low, between 5% to 10%, and not generally significantly different from placebo.100,120,121,125,126”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [100] Reisberg, 2003, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med source

      Not checked in the free run.

    • cites [120] Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA source

      Not checked in the free run.

    • cites [121] Porsteinsson, 2008, Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial, Curr Alzheimer Res source

      Not checked in the free run.

    • cites [125] Choi, 2011, Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study, Curr Med Res Opin source

      Not checked in the free run.

    • cites [126] Grossberg, 2013, The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors, CNS Drugs source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    There were no concerning safety signals or increased mortality with high-dose vitamin E.

    “there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [127] Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study, N Engl J Med source

      Not checked in the free run.

    • cites [128] Dysken, 2014, Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial, JAMA source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    Anti-AD medications can be maintained in late-stages to support basic psychomotor processes, praxis, functional communication, the behavioral responses required to assist caregivers to deliver basic activities of daily living care, and the elementary processes of movement and eating.

    “Anti-AD medications can be maintained in late-stages to support basic psychomotor processes, praxis, functional communication, the behavioral responses required to assist caregivers to deliver basic ADL care, and the elementary processes of movement and eating.”
    Quote in the paperSubstantial claim
40 of 40

  • The paper relies on this without support.

    AD clinical syndromes, Cognitive-Behavioral Syndromes (CBS) presumed to be due to AD, are heterogeneous, particularly in younger individuals (65 years of age or younger).

    “AD clinical (ADc) syndromes, Cognitive-Behavioral Syndromes (CBS) presumed to be due to AD, are heterogeneous, particularly in younger individuals (65 years of age or younger).”

  • The paper relies on this without support.

    Amnestic-MCI is greater than 90% associated with underlying AD pathology.

    “Amnestic-MCI is greater than 90% associated with underlying AD pathology.”

  • The paper relies on this without support.

    MCI significantly increases risk of annual progression to dementia (relative risk 6-8).

    “MCI significantly increases risk of annual progression to dementia (relative risk [RR] 6-8).”

  • The paper relies on this without support.

    Pathologic tangle findings correlate best with symptoms.

    “Pathologic tangle findings correlate best with symptoms.”

  • The paper relies on this without support.

    The MoCA is a good initial choice for detection; it takes approximately 8 to 12 minutes to administer, has good psychometric properties, acceptable sensitivity to detection of mild impairment, and is available in several forms and languages.

    “The MoCA is a good initial choice for detection; it takes approximately 8 to 12 minutes to administer, has good psychometric properties, acceptable sensitivity to detection of mild impairment, and is available in several forms and languages.”

  • The paper relies on this without support.

    Creutzfeldt-Jakob disease is on the differential diagnosis of atypical Alzheimer disease clinical spectrum syndromes when there is rapid onset and progression of symptoms over weeks to months.

    “Prion diseases are very rare but Creutzfeldt-Jakob disease is on the DDx of atypical ADc syndromes when there is rapid onset and progression of symptoms (over weeks to months).”

  • The paper relies on this without support.

    Overall poor and problem behaviors by the demented individual are not intentional but are due to disease, brain injury or damage, and diminished capacities.

    “It is important for caregivers to appreciate that overall poor and problem behaviors by the demented individual are not intentional (eg, to be mean, ornery, or vindictive) but are due to disease, brain injury or damage, and diminished capacities.”

  • The paper relies on this without support.

    Without accurate diagnosis and appropriate disclosure no care can be provided.

    “because without accurate diagnosis and appropriate disclosure no care can be provided”
8 of 8

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Low levels of cognitive, social, and physical activity may be linked to a greater risk of developing neurodegenerative diseases.

    “Low levels of cognitive, social, and physical activity may be linked to a greater risk of developing neurodegenerative diseases [3,83].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [83]

    Table 1 (Summary or Future Considerations; page unavailable) lists low physical activity and low cognitive reserve as risk factors for Alzheimer’s disease and dementia. The practical recommendations section encourages social and mental engagement, but does not identify low social activity as a risk factor. The claim also extends the paper’s AD-and-dementia discussion to neurodegenerative diseases generally. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Despite diverse additional mechanisms of action, no high-quality data evidence significant differences in efficacy among acetylcholinesterase inhibitors.

    “Despite the diverse additional mechanism of action, no high-quality data evidenced significant differences in their efficacy [27].”

    From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [27]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Memantine efficacy claim cites a gravitational-wave paper

    Minor

    Reference 112 is cited for a claim about memantine treatment effects, but its listed title concerns a search for gravitational waves, not memantine.

  • 2018 research framework is cited to an unrelated 2009 paper

    Minor

    The text cites reference 2 for the 2018 NIA-AA research framework, but reference 2 is a 2009 paper about treating vascular risk factors.

2 of 2

Cites

Flagged first, then by citations

6 of the 143 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Atri, A.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Atri, Alireza
ORCID
Atri, Alireza
Venue
Medical Clinics of North America
Publisher
Elsevier BV
Published
2019-03
Volume
103
Issue
2
Pages
263-293
ISSN
0025-7125 (ISSN-L)
DOI
10.1016/j.mcna.2018.10.009
OpenAlex
W2912556930
Semantic Scholar
14850f3937650b950a4f0acf73d3f53c6a2e1147
Cited by
623
References
143
Citations by year
2026: 61 · 2025: 111 · 2024: 131 · 2023: 122 · 2022: 90 · 2021: 65 · 2020: 34 · 2019: 7 · 2017: 1
FWCI
8.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Medical Clinics of North America (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • The American College of Radiology
  • AbbVie
  • Avid
  • Biogen
  • Lilly
  • Lundbeck
  • Merck
  • vTV
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, clinical spectrum, dementia diagnosis, clinical biomarkers, patient-caregiver dyads, shared decision-making, psychoeducation, pharmacotherapy, non-pharmacological treatment, disease progression, preclinical Alzheimer's disease, dementia prevention
MeSH terms
Alzheimer Disease, Diagnosis, Differential, Humans, Parkinson Disease, Biomarkers, Disease Progression, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review